ImmunityBio, Inc. (IBRX)
6.015
-0.06
(-0.91%)
USD |
NASDAQ |
Nov 13, 16:00
6.02
0.00 (0.00%)
After-Hours: 19:59
ImmunityBio Enterprise Value : 7.420B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 7.420B |
| November 11, 2026 | 8.058B |
| November 10, 2026 | 8.138B |
| November 09, 2026 | 8.526B |
| November 06, 2026 | 10.15B |
| November 05, 2026 | 9.483B |
| November 04, 2026 | 10.46B |
| November 03, 2026 | 9.781B |
| November 02, 2026 | 9.420B |
| October 30, 2026 | 9.781B |
| October 29, 2026 | 10.26B |
| October 28, 2026 | 10.33B |
| October 27, 2026 | 10.14B |
| October 26, 2026 | 9.271B |
| October 23, 2026 | 9.707B |
| October 22, 2026 | 9.803B |
| October 21, 2026 | 10.15B |
| October 20, 2026 | 10.29B |
| October 19, 2026 | 9.920B |
| October 16, 2026 | 10.73B |
| October 15, 2026 | 11.60B |
| October 14, 2026 | 11.50B |
| October 13, 2026 | 11.39B |
| October 12, 2026 | 11.73B |
| October 09, 2026 | 12.14B |
| Date | Value |
|---|---|
| October 08, 2026 | 11.50B |
| October 07, 2026 | 11.33B |
| October 06, 2026 | 11.27B |
| October 05, 2026 | 12.00B |
| October 02, 2026 | 11.90B |
| October 01, 2026 | 10.83B |
| September 30, 2026 | 11.00B |
| September 29, 2026 | 10.17B |
| September 28, 2026 | 9.845B |
| September 25, 2026 | 9.761B |
| September 24, 2026 | 9.972B |
| September 23, 2026 | 9.961B |
| September 22, 2026 | 10.66B |
| September 21, 2026 | 9.772B |
| September 18, 2026 | 9.803B |
| September 17, 2026 | 9.782B |
| September 16, 2026 | 9.203B |
| September 15, 2026 | 9.445B |
| September 14, 2026 | 9.687B |
| September 11, 2026 | 9.203B |
| September 10, 2026 | 9.003B |
| September 09, 2026 | 9.361B |
| September 08, 2026 | 9.603B |
| September 04, 2026 | 9.382B |
| September 03, 2026 | 9.498B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 92.52B |
| Sarepta Therapeutics, Inc. | 1.891B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Oncolytics Biotech, Inc. | 42.70M |
| Sangamo Therapeutics, Inc. | 37.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -184.56M |
| Revenue (Quarterly) | 48.84M |
| Total Expenses (Quarterly) | 233.39M |
| EPS Diluted (Quarterly) | -0.1741 |
| Gross Profit Margin (Quarterly) | 89.39% |
| Profit Margin (Quarterly) | -377.9% |
| Earnings Yield | -17.83% |
| Normalized Earnings Yield | -9.736 |